Monitoring of hepatitis b virus (HBV) DNA and risk of HBV reactivation in B-cell lymphoma: A prospective observational study

Clinical Infectious Diseases

Volumn 61, Issue 5, 2015, Pages 719-729

  Kusumoto, Shigeru ^a   Tanaka, Yasuhito ^b   Suzuki, Ritsuro ^c   Watanabe, Takashi ^d   Nakata, Masanobu ^e   Takasaki, Hirotaka ^f   Fukushima, Noriyasu ^g   Fukushima, Takuya ^h   Moriuchi, Yukiyoshi ⁱ   Itoh, Kuniaki ^j   Nosaka, Kisato ^k   Choi, Ilseung ^l   Sawa, Masashi ^m   Okamoto, Rumiko ⁿ   Tsujimura, Hideki ^o   Uchida, Toshiki ^p   Suzuki, Sachiko ^q   Okamoto, Masataka ^r   Takahashi, Tsutomu ^s   Sugiura, Isamu ^t   Onishi, Yasushi ^u   Kohri, Mika ^v   Yoshida, Shinichiro ^w   Sakai, Rika ^x   Kojima, Minoru ^y   Takahashi, Hiroyuki ^z   Tomita, Akihiro ^c   Maruyama, Dai ^d   Atsuta, Yoshiko ^c   Tanaka, Eiji ^aa   Suzuki, Takayo ^ab   Kinoshita, Tomohiro ^ac   Ogura, Michinori ^p   Mizokami, Masashi ^ad   Ueda, Ryuzo ^ae   more..

^a Department of Hematology and Oncology ^*  (United States)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

^e SAPPORO HOKUYU HOSPITAL   (Japan)

^f KANAGAWA CANCER CENTER   (Japan)

^g SAGA UNIVERSITY   (Japan)

^h NAGASAKI UNIVERSITY   (Japan)

ⁱ Sasebo Shiritsu Sogo Hospital   (Japan)

^j NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^k KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^l NATIONAL KYUSHU CANCER CENTER   (Japan)

^m ANJO KOSEI HOSPITAL   (Japan)

ⁿ TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^o CHIBA CANCER CENTER   (Japan)

^p NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^q HOKKAIDO CANCER CENTER   (Japan)

^r FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^s SHIMANE UNIVERSITY HOSPITAL   (Japan)

^t TOYOHASHI MUNICIPAL HOSPITAL   (Japan)

^u TOHOKU UNIVERSITY HOSPITAL   (Japan)

^v SAITAMA MEDICAL UNIVERSITY   (Japan)

^w NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^x YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^y TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^z YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^aa SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^ab SHIGA MEDICAL CENTER FOR ADULTS   (Japan)

^ac AICHI CANCER CENTER HOSPITAL   (Japan)

^ad 1 7 1 Kohnodai   (Japan)

^ae AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

HBV DNA monitoring; HBV reactivation; Preemptive antiviral therapy; Resolved HBV infection; Rituximab

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; HEPATITIS B SURFACE ANTIBODY; PIRARUBICIN; PREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE; VIRUS DNA; ANTIVIRUS AGENT;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY TITER; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; B CELL LYMPHOMA; DRUG FATALITY; FEMALE; GENE MUTATION; HEPATITIS B VIRUS; HUMAN; INFECTIOUS COMPLICATION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SEPTIC SHOCK; VACCINATION; VIRUS REACTIVATION; BLOOD; COMPLICATION; GENETICS; HEPATITIS B; LYMPHOMA, B-CELL; MIDDLE AGED; VIROLOGY;

AGED; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84942038524     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ344     Document Type: Article

References (32)

1. Lok AS, Liang RH, Chiu EK,Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182-8.
2. Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125:1742-9.
3. Yeo W, Chan PK, Ho WM, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004; 22: 927-34.
4. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001; 344:68-9.
5. Hui CK, Cheung WW, Zhang HY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006; 131:59-68.
6. Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27: 605-11.
7. Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 2009; 90:13-23.
8. Evens AM, Jovanovic BD, Su YC, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: metaanalysis and examination of FDA safety reports. Ann Oncol 2011; 22:1170-80.
9. Mitka M. FDA: increased HBV reactivation risk with ofatumumab or rituximab. JAMA 2013; 310:1664.
10. YeoW, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209-20.
11. Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008; 148:519-28.
12. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-39.
13. Weinbaum CM, Williams I, Mast EE, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008; 57(RR-8): 1-20.
14. Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009; 49 (5 suppl):S156-65.
15. Artz AS, Somerfield MR, Feld JJ, et al. American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol 2010; 28:3199-202.
16. Fukushima N, Mizuta T, Tanaka M, et al. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol 2009; 20:2013-7.
17. Yoshida T, Kusumoto S, Inagaki A, et al. Reactivation of hepatitis B virus in HBsAg-negative patients with multiple myeloma: two case reports. Int J Hematol 2010; 91:844-9.
18. Hsu C, Tsou HH, Lin SJ, et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology 2014; 59:2092-100.
19. Hochberger S, Althof D, Gallegos de Schrott R, Nachbaur N, Rock H, Leying H. Fully automated quantitation of hepatitis B virus (HBV) DNA in human plasma by the COBAS AmpliPrep/COBAS TaqMan system. J Clin Virol 2006; 35:373-80.
20. Goedel S, Rullkoetter M, Weisshaar S, Mietag C, Leying H, Boehl F. Hepatitis B virus (HBV) genotype determination by the COBAS Ampli-Prep/COBAS TaqMan HBV Test, v2.0 in serum and plasma matrices. J Clin Virol 2009; 45:232-6.
21. Shin IT, Tanaka Y, Tateno Y, Mizokami M. Development and public release of a comprehensive hepatitis virus database. Hepatol Res 2008; 38:234-43.
22. Kinn S, Akhavan S, Agut H, Thibault V. Performance of the DiaSorin LIAISON((R)) anti-HBs II for the detection of hepatitis B surface antibodies: comparison with the Abbott Architect anti-HBs assay. J Clin Virol 2011; 50:297-302.
23. Omata M, Ehata T, Yokosuka O, Hosoda K, Ohto M. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. N Engl J Med 1991; 324:1699-704.
24. Ozasa A, Tanaka Y, Orito E, et al. Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology 2006; 44:326-34.
25. Hammond SP, Borchelt AM, Ukomadu C, Ho VT, Baden LR, Marty FM. Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009; 15:1049-59.
26. Hadler SC, Francis DP, Maynard JE, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986; 315:209-14.
27. Launay O, van der Vliet D, Rosenberg AR, et al. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. JAMA 2011; 305:1432-40.
28. Awerkiew S, Daumer M, Reiser M, et al. Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient. J Clin Virol 2007; 38:83-6.
29. Ferreira R, Carvalheiro J, Torres J, et al. Fatal hepatitis B reactivation treated with entecavir in an isolated anti-HBs positive lymphoma patient: a case report and literature review. Saudi J Gastroenterol 2012; 18:277-81.
30. Byrd KK, Lu PJ, Murphy TV. Baseline hepatitis B vaccination coverage among persons with diabetes before implementing a U.S. recommendation for vaccination. Vaccine 2012; 30:3376-82.
31. Huang YH, Hsiao LT, Hong YC, et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 2013; 31:2765-72.
32. Kusumoto S, Tanaka Y, Mizokami M, Ueda R. Is antiviral prophylaxis necessary to prevent hepatitis B virus (HBV) reactivation in patients with HBV-resolved infection receiving rituximab-containing chemotherapy? J Clin Oncol 2013; 31:4480.